Adherence to anti-TNF therapy in inflammatory bowel diseases: A systematic review

Inflammatory Bowel Diseases

Volumn 19, Issue 7, 2013, Pages 1528-1533

  Lopez, Anthony ^a   Billioud, Vincent ^a   Peyrin Biroulet, Carina ^a   Peyrin Biroulet, Laurent ^a  

^a CHU NANCY BRABOIS   (France)

Author keywords

Adherence; Anti TNF; Inflammatory bowel disease

Indexed keywords

ADALIMUMAB; IMMUNOMODULATING AGENT; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ANKYLOSING SPONDYLITIS; ANXIETY; CLINICAL PHARMACY; CROHN DISEASE; DRUG EFFICACY; ENTERITIS; HUMAN; IMMUNOMODULATION; INTERNAL MEDICINE; MEDICATION COMPLIANCE; META ANALYSIS; MOOD; PATIENT ATTITUDE; PATIENT COMPLIANCE; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; SMOKING; SYRINGE; SYSTEMATIC REVIEW; TREATMENT CONTRAINDICATION; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MEDICATION ADHERENCE; PROGNOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84879117728     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e31828132cb     Document Type: Review

References (41)

1. Peyrin-Biroulet L, Oussalah A, Williet N, et al. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. Gut. 2011;60:930-936.
2. Williet N, Pillot C, Oussalah A, et al. Incidence of and impact of medications on colectomy in newly diagnosed ulcerative colitis in the era of biologics. Inflamm Bowel Dis. 2012:18:1641-1646.
3. Giorda C, Picariello R, Nada E, et al. The impact of adherence to screening guidelines and of diabetes clinics referral on morbidity and mortality in diabetes. PLoS One. 2012;7:e33839.
4. Bramley TJ, Gerbino PP, Nightengale BS, et al. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm. 2006;12:239-245.
5. Gross R, Bilker WB, Friedman HM, et al. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS. 2001;15:2109-2117.
6. Burkhart PV, Sabate E. Adherence to long-term therapies: evidence for action. J Nurs Scholarsh. 2003;35:207.
7. Kane S, Huo D, Aikens J, et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003;114:39-43.
8. Van Assche G, Vermeire S, Rutgeerts P. The potential for disease modification in Crohn's disease. Nat Rev Gastroenterol Hepatol. 2010;7:79-85.
9. Kane S, Shaya F. Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci. 2008;53:1020-1024.
10. Kane SV, Chao J, Mulani PM. Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn's disease patients. Adv Ther. 2009;26:936-946.
11. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50:105-116.
12. Morisky DE, Ang A, Krousel-Wood M, et al. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich). 2008;10:348-354.
13. Trindade AJ, Ehrlich A, Kornbluth A, et al. Are your patients taking their medicine? Validation of a new adherence scale in patients with inflammatory bowel disease and comparison with physician perception of adherence. Inflamm Bowel Dis. 2011;17:599-604.
14. Andrade SE, Kahler KH, Frech F, et al. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15:565-574; discussion 75-77.
15. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11:44-47.
16. Dezii CM. Persistence with drug therapy: a practical approach using administrative claims data. Manag Care. 2001;10:42-45.
17. Billioud V, Laharie D, Filippi J, et al. Adherence to adalimumab therapy in Crohn's disease: a French multicenter experience. Inflamm Bowel Dis. 2011;17:152-159.
18. Carter CT, Leher H, Smith P, et al. Impact of persistence with infliximab on hospitalizations in ulcerative colitis. Am J Manag Care. 2011;17:385-392.
19. Kitney L, Turner JM, Spady D, et al. Predictors of medication adherence in pediatric inflammatory bowel disease patients at the Stollery children's hospital. Can J Gastroenterol. 2009;23:811-815.
20. Mahic M, Skurtveit S, Selmer R, et al. Prevalence, incidence and persistence of etanercept and adalimumab in Norway 2005-2009. Pharmacoepidemiol Drug Saf. 2011;20:457-463.
21. Nahon S, Lahmek P, Saas C, et al. Socioeconomic and psychological factors associated with nonadherence to treatment in inflammatory bowel disease patients: results of the ISSEO survey. Inflamm Bowel Dis. 2011;17:1270-1276.
22. Liu Y, Yang M, Chao J, et al. Greater refill adherence to adalimumab therapy for patients using specialty versus retail pharmacies. Adv Ther. 2010;27:523-532.
23. Carter CT, Waters HC, Smith DB. Impact of infliximab adherence on Crohn's disease-related healthcare utilization and inpatient costs. Adv Ther. 2011;28:671-683.
24. Kane S, Dixon L. Adherence rates with infliximab therapy in Crohn's disease. Aliment Pharmacol Ther. 2006;24:1099-1103.
25. Angelucci E, Galletti B, De Nitto D, et al. Adherence to anti-tumor necrosis factor alpha in inflammatory bowel diseases: an Italian monocentric experience. Gut. 2011;60:A410.
26. Duncan J, Sastrillo M, Baker J, et al. An audit of adherence to anti-TNF therapy in patients with inflammatory bowel disease. J Crohn's Colitis. 2011;5:S86.
27. Liu Y, Yang M, Mulani PM, et al. Factors affecting Swedish patients' refill adherence and persistence to adalimumab therapy. J Crohn's Colitis. 2011;5:S59.
28. Kane SV, Loftus EV, Sandborn WJ, et al. Limited clinical utility of a self-administered tool for predicting medication adherence behavior in IBD. Gastroenterology. 2011;140:S-277.
29. Loftus EV Jr. A practical perspective on ulcerative colitis: patients' needs from aminosalicylate therapies. Inflamm Bowel Dis. 2006;12:1107-1113.
30. Moshkovska T, Stone MA, Clatworthy J, et al. An investigation of medication adherence to 5-aminosalicylic acid therapy in patients with ulcerative colitis, using self-report and urinary drug excretion measurements. Aliment Pharmacol Ther. 2009;30:1118-1127.
31. Moss AC, Chaudhary N, Tukey M, et al. Impact of a patient-support program on mesalamine adherence in patients with ulcerative colitis - a prospective study. J Crohns Colitis. 2009;4:171-175.
32. Bokemeyer B, Teml A, Roggel C, et al. Adherence to thiopurine treatment in out-patients with Crohn's disease. Aliment Pharmacol Ther. 2007;26:217-225.
33. Oliva-Hemker MM, Abadom V, Cuffari C, et al. Nonadherence with thiopurine immunomodulator and mesalamine medications in children with Crohn disease. J Pediatr Gastroenterol Nutr. 2007;44:180-184.
34. Wright S, Sanders DS, Lobo AJ, et al. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Gut. 2004;53:1123-1128.
35. Vrijens B, Vincze G, Kristanto P, et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336:1114-1117.
36. Sewitch MJ, Abrahamowicz M, Barkun A, et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol. 2003;98:1535-1544.
37. Blum MA, Koo D, Doshi JA. Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review. Clin Ther. 2011;33:901-913.
38. Hess LM, Raebel MA, Conner DA, et al. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother. 2006;40:1280-1288.
39. Christensen A, Christrup LL, Fabricius PE, et al. The impact of an electronic monitoring and reminder device on patient compliance with antihypertensive therapy: a randomized controlled trial. J Hypertens. 2010;28:194-200.
40. Strandbygaard U, Thomsen SF, Backer V. A daily SMS reminder increases adherence to asthma treatment: a three-month follow-up study. Respir Med. 2009;104:166-171.
41. Schurman JV, Cushing CC, Carpenter E, et al. Volitional and accidental nonadherence to pediatric inflammatory bowel disease treatment plans: initial investigation of associations with quality of life and disease activity. J Pediatr Psychol. 2011;36:116-125.